Effect of quercetin in treatment of stroke

Effect of quercetin supplementation on serum level of Asymmetric Dimethylarginine in patients in the chronic Phase of Ischemic stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202269142N1

Enrollment

Registered

2012-08-04

Start date

2012-06-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction( ischemic stroke). Cerebral infarction

Interventions

Intervention 1: Quercetin, oral capsule 500 mg, twice a day in two months. Intervention 2: placebo, oral capsules, twice a day in two months.

Treatment - Drugs

Placebo

Quercetin, oral capsule 500 mg, twice a day in two months

placebo, oral capsules, twice a day in two months

Eligibility

Sex/Gender

All

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients in the chronic phase of ischemic stroke ( 6 month- 2 years), 50- 75 years old, Body mass index between 25- 35. Exclusion criteria: Body mass index more than 35, Body mass index under 25, liver disease, kidney disease, hypo or hyper thyroid, Hemorrhagic stroke, Hormone therapy (HRT), intake of warfarin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Asymmetric Dimethylarginine. Timepoint: Start of survey and end of the second month. Method of measurement: Micromol/L with Human ADMA ELISA Kit.	—

Secondary

Measure	Time frame
Total cholesterol. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Triglyceride. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Low density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;High density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Fast blood glucose. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Blood pressure. Timepoint: Start of survey and end of the second month. Method of measurement: mmgh.	—

Measure

Time frame

Total cholesterol. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Triglyceride. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Low density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;High density lipoprotein. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Fast blood glucose. Timepoint: Start of survey and end of the second month. Method of measurement: mg/dl with kit.;Blood pressure. Timepoint: Start of survey and end of the second month. Method of measurement: mmgh.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Esmaeelzadeh

Tehran University of Medical Sciences

farnaz_2500@yahoo.com+98 21 2620 1922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026